News Janssen invests $350m in new European biologics production Janssen is to expand its biologics manufacturing capacity in Europe with a new $350 million (€300 million) investment in its existing site in Ireland.
Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars?
News Regeneron to develop long release Eylea successor Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
Articles Healthcare systems aren’t making the most of biosimilars: ph... Biosimilars could save European and US healthcare systems billions - but more needs to be done to maximise their benefits, writes Richard Staines.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends